MicroRNA-mediated metabolic reprogramming of chimeric antigen receptor T cells.

ABSTRACT: Advances made in chimeric antigen receptor (CAR) T cell therapy have revolutionized the treatment and management of certain cancers. Currently, B cell malignancies have been among the few cancers to which CAR T cells have shown persistent and resilient anti-tumor responses. A growing body of evidence suggests that the persistence of CAR T cells within patients following infusion is linked to the mitochondrial fitness of the CAR T cell, which could affect clinical outcomes. Analysis of CAR T cells from patients undergoing successful treatment has shown an increase in mitochondrial mass and fusion events, and a reduction in aerobic metabolism, highlighting the importance of mitochondria in CAR T cell function. Consequently, there has been recent interest and investment in approaches that foc

SUBMITTER: Rad SMAH 

PROVIDER: S-EPMC9322280 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature